{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:05:55Z","timestamp":1767139555707,"version":"build-2238731810"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-024-11276-4","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T09:47:15Z","timestamp":1737452835000},"page":"4213-4222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of interim [18F]FDG PET\/CT after immunotherapy-based combinations in extranodal NK\/T-cell lymphoma, nasal type"],"prefix":"10.1007","volume":"35","author":[{"given":"Lei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shatong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2659-6354","authenticated-orcid":false,"given":"Yujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"11276_CR1","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/annonc\/mdn147","volume":"19","author":"TM Kim","year":"2008","unstructured":"Kim TM, Lee S-Y, Jeon YK et al (2008) Clinical heterogeneity of extranodal NK\/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 19:1477\u20131484. https:\/\/doi.org\/10.1093\/annonc\/mdn147","journal-title":"Ann Oncol"},{"key":"11276_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1365-2141.2011.08982.x","volume":"156","author":"WZ Ai","year":"2012","unstructured":"Ai WZ, Chang ET, Fish K et al (2012) Racial patterns of extranodal natural killer\/T-cell lymphoma, nasal type, in California: a population-based study. Br J Haematol 156:626\u2013632. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08982.x","journal-title":"Br J Haematol"},{"key":"11276_CR3","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","volume":"113","author":"W Au","year":"2009","unstructured":"Au W, Weisenburger DD, Intragumtornchai T et al (2009) Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113:3931\u20133937. https:\/\/doi.org\/10.1182\/blood-2008-10-185256","journal-title":"Blood"},{"key":"11276_CR4","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1182\/blood-2008-05-160176","volume":"112","author":"Y-X Li","year":"2008","unstructured":"Li Y-X, Fang H, Liu Q-F et al (2008) Clinical features and treatment outcome of nasal-type NK\/T-cell lymphoma of Waldeyer ring. Blood 112:3057\u20133064. https:\/\/doi.org\/10.1182\/blood-2008-05-160176","journal-title":"Blood"},{"key":"11276_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","volume":"15","author":"E Tse","year":"2022","unstructured":"Tse E, Zhao W-L, Xiong J, Kwong Y-L (2022) How we treat NK\/T-cell lymphomas. J Hematol Oncol 15:74. https:\/\/doi.org\/10.1186\/s13045-022-01293-5","journal-title":"J Hematol Oncol"},{"key":"11276_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108192","volume":"26","author":"L He","year":"2023","unstructured":"He L, Chen N, Dai L, Peng X (2023) Advances and challenges of immunotherapies in NK\/T cell lymphomas. iScience 26:108192. https:\/\/doi.org\/10.1016\/j.isci.2023.108192","journal-title":"iScience"},{"key":"11276_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","volume":"17","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Yoon DH, Jaccard A et al (2016) A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol 17:389\u2013400. https:\/\/doi.org\/10.1016\/S1470-2045(15)00533-1","journal-title":"Lancet Oncol"},{"key":"11276_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ajh.25878","volume":"95","author":"S-N Qi","year":"2020","unstructured":"Qi S-N, Yang Y, Zhang Y-J et al (2020) Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: a China Lymphoma Collaborative Group study. Am J Hematol 95:1047\u20131056. https:\/\/doi.org\/10.1002\/ajh.25878","journal-title":"Am J Hematol"},{"key":"11276_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"11276_CR10","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048\u20133058. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229","journal-title":"J Clin Oncol"},{"key":"11276_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington SF, Kluge R (2017) FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 44:97\u2013110. https:\/\/doi.org\/10.1007\/s00259-017-3690-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11276_CR12","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/S2352-3026(15)00002-2","volume":"2","author":"SJ Kim","year":"2015","unstructured":"Kim SJ, Choi JY, Hyun SH et al (2015) Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer\/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol 2:e66\u2013e74. https:\/\/doi.org\/10.1016\/S2352-3026(15)00002-2","journal-title":"Lancet Haematol"},{"key":"11276_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-020-00379-y","volume":"21","author":"H Li","year":"2021","unstructured":"Li H, Shao G, Zhang Y et al (2021) Nomograms based on SUVmax of 18F-FDG PET\/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma. Cancer Imaging 21:9. https:\/\/doi.org\/10.1186\/s40644-020-00379-y","journal-title":"Cancer Imaging"},{"key":"11276_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/RLU.0000000000000892","volume":"40","author":"C Jiang","year":"2015","unstructured":"Jiang C, Su M, Kosik RO et al (2015) The Deauville 5-point scale improves the prognostic value of interim FDG PET\/CT in extranodal natural killer\/T-cell lymphoma. Clin Nucl Med 40:767\u2013773. https:\/\/doi.org\/10.1097\/RLU.0000000000000892","journal-title":"Clin Nucl Med"},{"key":"11276_CR15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","volume":"40","author":"E Itti","year":"2013","unstructured":"Itti E, Meignan M, Berriolo-Riedinger A et al (2013) An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax. Eur J Nucl Med Mol Imaging 40:1312\u20131320. https:\/\/doi.org\/10.1007\/s00259-013-2435-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11276_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.critrevonc.2016.07.003","volume":"106","author":"HJA Adams","year":"2016","unstructured":"Adams HJA, Kwee TC (2016) Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis. Crit Rev Oncol Hematol 106:55\u201363. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"11276_CR17","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","volume":"36","author":"U D\u00fchrsen","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B et al (2018) Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol 36:2024\u20132034. https:\/\/doi.org\/10.1200\/JCO.2017.76.8093","journal-title":"J Clin Oncol"},{"key":"11276_CR18","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood.2019003277","volume":"135","author":"H Sch\u00f6der","year":"2020","unstructured":"Sch\u00f6der H, Polley M-YC, Knopp MV et al (2020) Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood 135:2224\u20132234. https:\/\/doi.org\/10.1182\/blood.2019003277","journal-title":"Blood"},{"key":"11276_CR19","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2967\/jnumed.123.265871","volume":"64","author":"E Itti","year":"2023","unstructured":"Itti E, Blanc-Durand P, Berriolo-Riedinger A et al (2023) Validation of the \u0394SUVmax for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical trial. J Nucl Med 64:1706\u20131711. https:\/\/doi.org\/10.2967\/jnumed.123.265871","journal-title":"J Nucl Med"},{"key":"11276_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2967\/jnumed.113.131946","volume":"55","author":"P-L Khong","year":"2014","unstructured":"Khong P-L, Huang B, Lee EYP et al (2014) Midtreatment 18F-FDG PET\/CT scan for early response assessment of SMILE therapy in natural killer\/T-cell lymphoma: a prospective study from a single center. J Nucl Med 55:911\u2013916. https:\/\/doi.org\/10.2967\/jnumed.113.131946","journal-title":"J Nucl Med"},{"key":"11276_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/RLU.0000000000002440","volume":"44","author":"C Qin","year":"2019","unstructured":"Qin C, Yang S, Sun X et al (2019) 18F-FDG PET\/CT for prognostic stratification of patients with extranodal natural killer\/T-cell lymphoma. Clin Nucl Med 44:201\u2013208. https:\/\/doi.org\/10.1097\/RLU.0000000000002440","journal-title":"Clin Nucl Med"},{"key":"11276_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11276_CR23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M et al (2009) Report on the first International Workshop on Interim-PET-scan in lymphoma. Leuk Lymphoma 50:1257\u20131260. https:\/\/doi.org\/10.1080\/10428190903040048","journal-title":"Leuk Lymphoma"},{"key":"11276_CR24","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"key":"11276_CR25","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252\u20137259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713","journal-title":"Clin Cancer Res"},{"key":"11276_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","volume":"6","author":"R Tao","year":"2021","unstructured":"Tao R, Fan L, Song Y et al (2021) Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther 6:365. https:\/\/doi.org\/10.1038\/s41392-021-00768-0","journal-title":"Signal Transduct Target Ther"},{"key":"11276_CR27","doi-asserted-by":"publisher","first-page":"00066","DOI":"10.1016\/S2352-3026(24)00066-8","volume":"S2352-3026","author":"X-P Tian","year":"2024","unstructured":"Tian X-P, Cai J, Xia Y et al (2024) First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial. Lancet Haematol S2352-3026:00066\u201300068. https:\/\/doi.org\/10.1016\/S2352-3026(24)00066-8","journal-title":"Lancet Haematol"},{"key":"11276_CR28","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 374:2419\u20132429. https:\/\/doi.org\/10.1056\/NEJMoa1510093","journal-title":"N Engl J Med"},{"key":"11276_CR29","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M et al (2024) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/28291393\/. Accessed 18 Apr 2024"},{"key":"11276_CR30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","volume":"130","author":"R-O Casasnovas","year":"2017","unstructured":"Casasnovas R-O, Ysebaert L, Thieblemont C et al (2017) FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood 130:1315\u20131326. https:\/\/doi.org\/10.1182\/blood-2017-02-766691","journal-title":"Blood"},{"key":"11276_CR31","unstructured":"Borchmann P, Pl\u00fctschow A, Kobe C et al (2024) PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/33539742\/. Accessed 18 Apr 2024"},{"key":"11276_CR32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41571-023-00799-2","volume":"20","author":"JP Alderuccio","year":"2023","unstructured":"Alderuccio JP, Kuker RA, Yang F, Moskowitz CH (2023) Quantitative PET-based biomarkers in lymphoma: getting ready for primetime. Nat Rev Clin Oncol 20:640\u2013657. https:\/\/doi.org\/10.1038\/s41571-023-00799-2","journal-title":"Nat Rev Clin Oncol"},{"key":"11276_CR33","unstructured":"Biggi A, Gallamini A, Chauvie S et al (2024) International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/23516309\/. Accessed 18 Apr 2024"},{"key":"11276_CR34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.122.264740","volume":"64","author":"L Michaud","year":"2023","unstructured":"Michaud L, Bantilan K, Mauguen A et al (2023) Prognostic value of 18F-FDG PET\/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen. J Nucl Med 64:536\u2013541. https:\/\/doi.org\/10.2967\/jnumed.122.264740","journal-title":"J Nucl Med"},{"key":"11276_CR35","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","volume":"85","author":"HJA Adams","year":"2016","unstructured":"Adams HJA, Kwee TC (2016) Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. Eur J Radiol 85:1963\u20131970. https:\/\/doi.org\/10.1016\/j.ejrad.2016.08.011","journal-title":"Eur J Radiol"},{"key":"11276_CR36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00259-013-2443-6","volume":"40","author":"C-Y Kim","year":"2013","unstructured":"Kim C-Y, Hong CM, Kim D-H et al (2013) Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET\/CT in patients with extranodal NK\/T-cell lymphoma. Eur J Nucl Med Mol Imaging 40:1321\u20131329. https:\/\/doi.org\/10.1007\/s00259-013-2443-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11276_CR37","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.02367","volume":"41","author":"H Huang","year":"2023","unstructured":"Huang H, Tao R, Hao S et al (2023) Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study. J Clin Oncol 41:3032\u20133041. https:\/\/doi.org\/10.1200\/JCO.22.02367","journal-title":"J Clin Oncol"},{"key":"11276_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.766200","volume":"13","author":"P Sun","year":"2022","unstructured":"Sun P, Wang Y, Yang H et al (2022) Combination of anti-PD-1 antibody, anlotinib and pegaspargase \u201csandwich\u201d with radiotherapy in localized natural killer\/T cell lymphoma. Front Immunol 13:766200. https:\/\/doi.org\/10.3389\/fimmu.2022.766200","journal-title":"Front Immunol"},{"key":"11276_CR39","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/ajh.26922","volume":"98","author":"P Sun","year":"2023","unstructured":"Sun P, Li Y, Li C et al (2023) A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer\/T-cell lymphoma. Am J Hematol 98:1043\u20131051. https:\/\/doi.org\/10.1002\/ajh.26922","journal-title":"Am J Hematol"},{"key":"11276_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-024-01782-8","volume":"9","author":"J Xiong","year":"2024","unstructured":"Xiong J, Cheng S, Gao X et al (2024) Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma. Signal Transduct Target Ther 9:62. https:\/\/doi.org\/10.1038\/s41392-024-01782-8","journal-title":"Signal Transduct Target Ther"}],"updated-by":[{"DOI":"10.1007\/s00330-025-11586-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000}}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11276-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-11276-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11276-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:41:40Z","timestamp":1749814900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-11276-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["11276"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-11276-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the original version of this article, the given and family names of Wei Fan were interchanged by mistake and has since been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00330-025-11586-1","URL":"https:\/\/doi.org\/10.1007\/s00330-025-11586-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is the corresponding author Yujing Zhang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent from all subjects (patients) in this study was obtained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No study subjects or cohorts have been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}